| Document |
Document Title |
|
WO/2016/072941A1 |
This invention relates to a method for preparing diethanolamine derivatives having the structure (I): Formula (I); wherein Formula (II); R1 represents structure (II) R2 represents hydrogen or structure (II); X represents hydrogen, alkali...
|
|
WO/2016/065435A2 |
New chelators such as H3L1, H3L2, H3L3, H3L26 and derivatives were synthesized for the complexation of {Al18F}2+. These new chelators are able to complex {AI18F}2+ with good radiochemical yields using a labeling temperature of 37 °C. Th...
|
|
WO/2016/058875A1 |
Aqueous solution containing in the range of from 60.5 to 75 % by weight of a mixture of trialkalimetal salts of the L-and D-enantiomers of methyl glycine diacetic acid (MGDA), said mixture containing predominantly the respective L-isomer...
|
|
WO/2016/061393A1 |
Monomethyl and monoethyl fumarate prodrugs, pharmaceutical compositions comprising the monomethyl and monoethyl fumarate prodrugs, and methods of using monomethyl and monoethyl fumarate prodrugs and pharmaceutical compositions for treati...
|
|
WO/2014/133291A9 |
The present invention relates to: a method for easily preparing (2RS)-amino-(3S)-hydroxy-butyric acid, which is a chiral amino acid, in a high yield and a high purity using a chemical synthesis and an enzymatic reduction reaction; an int...
|
|
WO/2016/055015A1 |
Disclosed is a method for synthesizing a sitagliptin intermediate, the method comprising: under the existence of transition metal catalyst of chiral phosphine ligand and hydrogen, conducting asymmetrical reduction ammonification reaction...
|
|
WO/2016/053649A1 |
A method for treating a low value carbon source to produce biologically labile carbon, comprising the steps of oxidizing the low value carbon source with at least one oxidizing agent to produce a modified, partially solubilized low value...
|
|
WO/2016/037053A1 |
This invention provides for a compound of formula (I), or a pharmaceutically acceptable salt thereof, wherein RA, RB, R2 and R4 are defined herein. The compounds of formula (I) and pharmaceutically acceptable salts thereof are cationic l...
|
|
WO/2016/031463A1 |
Provided is the possibility of a novel application of an optical vortex. For this purpose, a method for producing amino acid crystals according to one aspect of the present invention is characterized by comprising irradiating a saturated...
|
|
WO/2016/027699A1 |
The purpose of the present invention is to provide a cationic lipid which, when used as a lipid membrane structure that is a carrier for functional nucleic acid delivery, achieves a higher intracellular delivery efficiency than with a co...
|
|
WO/2016/026196A1 |
Disclosed are a novel double long chain ester-based quaternary-N and synthesis technique thereof, the synthesis steps thereof being as follows: an esterification reaction of halogenated carboxylic acid: mixing a halogenated carboxylic ac...
|
|
WO/2016/021683A1 |
The present invention provides: a technique which enables an active ingredient (such as a nucleic acid) to be introduced into many types of cell with excellent efficiency; and a compound used in said technique. The present invention prov...
|
|
WO/2016/017713A1 |
Provided is an oil and water separation device that can easily and inexpensively separate and collect the oil component from a mixed fluid comprising water and oil. This oil and water separation device gravity-filters a mixed fluid compr...
|
|
WO/2016/017754A1 |
This filter medium for separating a liquid containing water and oil and having a channel for the liquid also has a substrate constituting the channel, and one or more types of nitrogen-containing fluorine-based compounds present on the s...
|
|
WO/2016/017768A1 |
This hydrophilic oil-repellent complex includes one or more types of nitrogen-containing fluorine compounds, and an inorganic compound that has an electric charge or ionic group. The nitrogen-containing fluorine compound includes, within...
|
|
WO/2016/016582A1 |
The present invention relates to a compound of general formula (I), wherein: - n is an integer equal to 1, 2 or 3; - m is an integer equal to 1, 2 or 3; and - M is selected from the alkali metals with the exception of sodium, the alkalin...
|
|
WO/2016/017686A1 |
This hydrophilic oil repellent agent includes at least one species of nitrogen-containing fluorine compound. The nitrogen-containing fluorine compound includes, in the molecule thereof, any one hydrophilicity-imparting group selected fro...
|
|
WO/2016/013032A1 |
The present invention discloses tricyclic compounds of formula (I) or salt thereof and their process for synthesis. Further, the present invention relates to the use of these novel tricyclic compounds of formula (I) or salt thereof as in...
|
|
WO/2016/011920A1 |
Provided are artificially synthesized modified mono-methylated lysines and modified mono-methylated lysine derivatized polypeptides. Also provided is an antibody produced by using this modified mono-methylated lysine and modified mono-me...
|
|
WO/2016/008393A1 |
The present invention relates to a ceftaroline fosamil amino acid salt and crystal thereof. The ceftaroline fosamil is represented by formula I, and the amino acid is aspartic acid or glutamic acid. The ceftaroline fosamil amino acid sal...
|
|
WO/2015/199952A1 |
Compounds are provided having the following structure: (I) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1a, R1b, R2a, R2b, R3a, R3b, R4a, R4b, R5, R6, R7, R8, R9, L1, L2, a, b, c, d and e are as defin...
|
|
WO/2015/197379A1 |
Formulations, containing (A) at least one compound selected from methyl glycine diacetate (MGDA) and glutamic acid diacetate (GLDA) and the salts thereof, (B) at least one graft polymer, constructed of (a) at least one graft base, select...
|
|
WO/2015/191433A1 |
Novel synthesized amino acids of glutamine and lysine that are directly PEGylated with small, monodisperse PEGs, and a novel process for creating novel amino acid monomers using PEGylation. These amino acids are readily incorporated into...
|
|
WO/2015/189068A1 |
The present invention relates to the preparation of β-substituted γ-amino carboxylic acids, preferably in enantiomerically enriched or even enantiomerically pure form, by a one-pot conversion of a β-substituted γ-nitro dicarboxylic a...
|
|
WO/2015/189862A1 |
Described herein is the general synthesis of chiral amine from vinyl nitro compounds using Josiphos catalyst. The process is applied to develop a novel route to Sitagliptin (a DPP-IV inhibitor).
|
|
WO/2015/183132A1 |
A salt of zinc or copper (II) which can be used as a biocide, having the general formula CH2=C(R1)COO-M-OCOR2(OH)m(COOH)n, where M is Zn or Cu, R1 is selected from the group including hydrogen and methyl, R2 is a substituted С1-С5 alky...
|
|
WO/2015/180486A1 |
The present invention belongs to the technical field of medicine. The present invention relates to a synthesis process of 2-[(2,6-dichlorophenyl)amino]phenylacetic acid 1-(acetoxyl)ethyl ester and the preparation of a fat emulsion inject...
|
|
WO/2015/181304A1 |
The invention relates to a method for preparing a salt of acetylsalicylic acid and a basic amino acid, comprising mixing a solution of acetylsalicylic acid and a solution of said basic amino acid in a reactor, at a temperature lower than...
|
|
WO/2015/178753A1 |
The invention relates to a method for producing branched geminal zwitterionic liquids based on bis-N,N-dialkyl-N-polyether-betaine or bis-N,N-dialkenyl-N-polyether-betaine or bis-N,N-dicycloalkyl-N-polyether-betaine or bis-N,N-diaryl-N-p...
|
|
WO/2015/179743A1 |
The invention provides compounds and related compositions that include peptide sequences for enabling transduction of a cargo into cells. The invention further includes methods for screening a library of such compounds.
|
|
WO/2015/156398A1 |
Provided are: a biocatalyst solvent that can be stored for a long period of time and that can dissolve a high concentration of a biocatalyst from low temperatures to high temperatures while retaining the activity of the biocatalyst; and ...
|
|
WO/2015/157597A1 |
Copper-catalyzed radiofluorination of iodonium salts, iodonium salts, and compounds obtained by copper-catalyzed radiofluorination of iodonium salts are disclosed. Diagnostic and therapeutic methods involving such compounds also are disc...
|
|
WO/2015/157239A1 |
The disclosure provides for metal organic frameworks (MOFs) which comprise a plurality of SBUs linked together by functionalized or multivariate BTB-based linking ligands. The disclosure further provides for the use of these MOFs in vari...
|
|
WO/2015/152128A1 |
Disclosed is an amino acid that can be prevented from being incorporated into normal cells and selectively incorporated into tumor cells, even when used in a PET diagnostic tracer. Also disclosed are an amino acid precursor, a production...
|
|
WO/2015/151013A1 |
The present invention relates to a process for the preparation of Levothyroxine and salts thereof. The process described in the present invention provides increase in the yields and purity comprising the use of sodium iodide and sodium h...
|
|
WO/2015/151068A1 |
Novel synthetic analogues of 3-iodothyronamine of formula (I), pharmaceutical compositions containing the same, and medical uses thereof are described.
|
|
WO/2015/152234A1 |
The present invention addresses the issue of providing an acylcarnitine composition that is easy to handle in a liquid state and has long-term storage stability. Said issue is solved by an acylcarnitine composition characterized by havin...
|
|
WO/2015/152273A1 |
This fluorine-containing compound is a nitrogen atom-containing perfluoroalkyl (meth)acrylate in which a plurality of straight-chain perfluoroalkyl groups having a carbon number of 6 or less have been bonded via a nitrogen atom, wherein ...
|
|
WO/2015/149599A1 |
Disclosed is a method for preparing an iminodisuccinate chelating agent. The reaction raw materials comprise a raw material A, a raw material B, an alkali metal hydroxide, and water, and the pH value of the reaction system is in a range ...
|
|
WO/2015/145602A1 |
The present invention provides a composition which contains (A) one or more compounds represented by general formula (1) and (B) one or more compounds selected from the group consisting of diethylenetriaminepentaacetic acid and salts the...
|
|
WO/2015/146881A1 |
The present invention is a process for producing a 1-arylimino-2-vinylcyclopropanecarboxylic acid derivative represented by formula (2) in a yield close to that attained with lithium t-butoxide, preferably in a yield higher than that att...
|
|
WO/2015/138969A1 |
Novel compounds having a formula embodiments of a method of making the same, and of a composition comprising them are disclosed herein. Also disclosed are embodiments of a method of treating or preventing a metabolic disorder in a subjec...
|
|
WO/2015/132519A1 |
The invention relates to a method for preparing a derivative of 11-aminoundecanoic acid or 12-aminododecanoic acid, or an ester of the latter, having the formula R-NH-(CH2)n-COOR', wherein n has a value of 10 or 11, R is an alkyl, fluoro...
|
|
WO/2015/128488A1 |
The present invention relates to novel compounds, e.g.for use as a medicament. In particular,the present invention relates to novel prodrugs of monomethyl fumarate (MMF) suitable as a medicament, preferably in the treatment and/or preven...
|
|
WO/2015/127558A1 |
Compositions for eliciting acute micturition (voiding activity) in subjects having a spinal cord injury (SCI subject) are described herein. The compositions may generally comprise one or more of a 5-HT (5-hydroxytryptamine, serotonin) re...
|
|
WO/2015/124290A1 |
The invention relates to novel compounds having fluoridated terminal groups, to the use thereof as surface-active substances, and to agents containing said compounds.
|
|
WO2015120821A1 |
Disclosed are water-soluble propofol derivatives, preparation method thereof, anaesthesia method using same, use thereof as prodrugs and use thereof for preparing vein dope medicines. The water-soluble propofol derivatives have a general...
|
|
WO/2015/120820A1 |
The present invention discloses a class of carboxylic acid derivatives and use thereof in preparation of prodrugs. The carboxylic acid derivatives have the general formula (I): R1 being H or an alkyl; X being H or F; Y being F or a fluor...
|
|
WO/2015/117146A1 |
β-Substituted -amino acids, β-substituted γ-amino acid derivatives, and β-substituted γ-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted γ-amino acid derivatives and Î...
|
|
WO/2015/116786A1 |
In one aspect, the invention relates to compounds having the formula (I): where R1-R6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another asp...
|
